Neupharma
- Company typePrivate
- Founded2012
- HeadquartersImola, Italy
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Neupharma firmographics
Firmographics- Name
- Neupharma
- Legal name
- NEUPHARMA S.r.l.
- Website
- https://neupharma.it
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Neupharma industry classification
Industry- Product category
- Specialty Pharmaceuticals (Cystic Fibrosis & Rare Diseases)
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
- akta.pro secondary industries
- Nephrology & Urology Pharmaceuticals (HLAIAAAM), Probiotics & Digestive Health Supplements (CRADAGAF)
Keywords
Where Neupharma is headquartered
LocationHeadquarters
- HQ city
- Imola
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Neupharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Pharmaceutical Distribution: Distribution of inhaled antibiotics (Colfinair, Vantobra) for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Products are prescription-only medications patented by PARI Pharma GmbH.
- Medical Devices: Distribution of PARI medical devices including eFlow nebulizers, nasal washing devices (Naridek), and related respiratory therapy equipment.
- Foods for Medical Purposes: Sale of specialized nutritional products including vitamin supplements (DKX, DKX Plus, DALVIK), WADI saline supplementation tablets, and Yoxa probiotic sachets for CF patients.
- FRIP Low-Phosphorus Foods: Distribution partnership with Italian dairies for FRIP branded low-phosphorus cheeses for nephrology patients, presented at medical congresses.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Prescription pharmaceutical products for cystic fibrosis treatment |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
Neupharma product offering
Product offeringCore offering
Neupharma is an Italian specialty pharmaceutical company that distributes and markets prescription drugs, medical devices, and foods for special medical purposes focused on cystic fibrosis care. Its portfolio includes inhaled antibiotics (Colfinair, Vantobra) for Pseudomonas aeruginosa infections, PARI respiratory therapy devices and nebulizers, nasal washing devices (Naridek), and CF-targeted nutritional supplements (DKx, DKD, WADI, DALVIK, Yoxa). The company is the exclusive Italian distributor for PARI Pharma GmbH and also distributes the FRIP low-phosphorus cheese line for nephrology patients.
Product overview
Neupharma is a young, modern Italian pharmaceutical company focused on innovation and rare diseases, particularly cystic fibrosis. The product portfolio comprises three main categories: (1) Inhaled Antibiotic Therapies including Colfinair (colistimethate sodium) and Vantobra (tobramycin) for chronic Pseudomonas aeruginosa infection, distributed in partnership with PARI Pharma GmbH; (2) Medical Devices including PARI BOY FAMILY 2.0 nebulizers with dedicated Service DM PARI online catalogue, and Naridek Bag nasal wash devices; (3) Foods for Medical Purposes and Supplements including vitamin D formulations (DKD, Dkx, Dkx Plus), DHA supplements (DALVIK), salt supplementation tablets (WADI), and lactic ferments (Yoxa). Neupharma also holds 15% ownership in PlumeStars, a Parma-based research company developing orphan inhalation products, and distributes the FRIP branded low-phosphorus cheese line for nephrology patients.
Differentiator
Problem solved
Functional benefit
Brands
- FRIP: Patent-pending cheese brand for patients who need to limit phosphorus intake, developed for nephrology patients.
- WADI
- DALVIK NEUPHARMA
- Yoxa
- DKx
- DKD
- Colfinair
- Vantobra
- Naridek Bag
Products and services
- Colfinair (Colistimethate Sodium) Inhaled antibiotic therapy (colistimethate sodium powder for solution for inhalation) for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients, delivered using the PARI eFlow Rapid nebulizer. Prescription pharmaceutical product.
- Vantobra (Tobramycin) Inhaled antibiotic therapy (170mg/1.7ml tobramycin solution for inhalation) for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients, delivered using the PARI eFlow Rapid nebulizer with a drug-specific customized handset. Prescription pharmaceutical product.
- PARI BOY FAMILY 2.0 High-tech aerosol therapy nebulizer device for respiratory treatment in cystic fibrosis and other respiratory conditions, distributed by Neupharma in partnership with PARI Pharma GmbH.
- Naridek Bag Medical device for nasal washing using non-ionic surfactant in 250ml sterile isotonic solution bags, intended for prevention of respiratory tract colonization in cystic fibrosis patients. Each package contains 6 ready-to-use sterile bags plus connector hoses.
- Dkx Combined vitamin supplementation in a single capsule containing fat-soluble vitamins, formulated for cystic fibrosis patients.
- Dkx Plus Comprehensive syrup-form supplement containing fat-soluble vitamins, DHA, minerals and antioxidants for cystic fibrosis patients.
- DKD Oral soluble film for vitamin D supplementation in cystic fibrosis patients, addressing hypovitaminosis D.
- WADI Salt supplementation tablets containing Sodium Chloride and Magnesium for cystic fibrosis patients who lose excessive sodium and chlorine through sweat, helping prevent dehydration.
- DALVIK Neupharma 400mg softgel capsules of algae-derived DHA (docosahexaenoic acid) for dietary supplementation.
- Yoxa Orosolubile Food supplement in orodispersible granule sachets containing live lactic ferments (probiotics) for cystic fibrosis patients.
- FRIP Cheese Patented FRIP brand of Italian cheeses with low absorbable phosphorus content (Formaggio a Ridotto Fosforo Assorbibile) designed for the diet of nephropathic patients requiring phosphate restriction, produced through a network of Italian dairies.
Quantifiable outcome
- Phase 1 clinical trial completed with positive safety and tolerability results for inhaled teicoplanin in CF patients
- +2 more outcomes
Companies that use Neupharma
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
Neupharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Neupharma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Curatis Holding AGcoreIn March 2026, Neupharma signed an exclusive licensing agreement for corticorelin in Japan with potential payments of up to CHF 83.5 million plus royalties of up to 20% on future sales. Corticorelin is being developed for peritumoral brain edema with FDA-validated development plan for pivotal Phase 3 trial.
- PlumeStarsminorNeupharma acquired 15% of PlumeStars, a research company based in Parma dedicated to development of orphan products for rare diseases with specific know-how in inhalation formulations. PlumeStars has four innovative formulations in its portfolio and several international patents.
- Rare Partners Srl Impresa SocialecoreCollaboration for development of inhaled teicoplanin formulation for MRSA lung infections in cystic fibrosis patients. Rare Partners contributed to obtaining orphan drug designations from both European Commission and FDA. Phase 1 clinical trial was conducted successfully.
- PARI GmbHcoreNeupharma has been the exclusive distributor for all PARI medical devices and drugs in Italy since 2014. PARI specializes in high-tech respiratory therapy devices including the PARI BOY FAMILY 2.0 nebulizers. The partnership combines pharmacological therapies for cystic fibrosis with PARI's medical device production expertise.
- AitecaminorE-commerce partner for PARI medical device sales through their platform, facilitating online access to respiratory therapy devices.
- Italian Dairies (Latteria Antigoriana, Caseificio Rosso, Bio Carioni, Montegrappa, Campagnola, Iaquilat, Bufala Dolce Nera, Caseificio La Cava, Caseificio Artigianale Giomaria Riu)minorMultiple Italian dairies produce and distribute FRIP branded low-phosphorus cheeses for nephrology patients. Products available through dedicated website www.myfrip.com.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Neupharma competitors and assessment
Company assessmentEmerging players
- Atea Pharmaceuticals: Clinical-stage biotech developing inhaled antiviral and respiratory therapies. Tangentially comparable through inhaled-delivery expertise for orphan/respiratory indications.
- Savara Inc. Clinical-stage biotech developing inhaled therapeutics for rare pulmonary diseases, including molgramostim for autoimmune pulmonary alveolar proteinosis. Comparable focus on inhaled delivery for orphan lung indications.
Broad incumbents
- Vertex Pharmaceuticals: Dominant global player in CF therapeutics (Trikafta/Kaftrio, Kalydeco, Orkambi), shaping the standard of care that Neupharma's CF antibiotic and respiratory device portfolio is designed to complement. Comparable patient population and indication focus.
- Vectura Group: Inhaled drug delivery technology and formulation specialist whose platform underpins multiple inhaled CF and respiratory products. Comparable to PlumeStars (Neupharma's 15%-owned affiliate) and to Neupharma's PARI eFlow distribution franchise.
- Chiesi Farmaceutici: Italian-headquartered multinational pharmaceutical company with deep presence in rare diseases, neonatology, and respiratory care. Operates in the same Italian ecosystem as Neupharma, with overlapping CF and specialty-pharma channels.
- Zambon: Italian privately-held pharmaceutical group with respiratory and rare-disease portfolios. Same home market, similar specialty-pharma positioning, comparable geographic dependence on Italy and Europe.
- Recordati S.p.A. Mid-size Italian pharma with a rare-disease business (Recordati Rare Diseases) and established European commercial infrastructure. Relevant benchmark for an Italian specialty pharma seeking to scale niche franchises.
Regional players
- Dompé Farmaceutici: Italian biopharma combining proprietary R&D with specialty distribution across rare diseases and primary care, with a footprint in ophthalmology and inflammation. Comparable Italian specialty-pharma operating model.
Direct peers
- Insmed Incorporated: US-based specialty pharma commercializing inhaled antibiotics (Arikayce) for chronic lung infections caused by rare pathogens. Closest business-model analogue to Neupharma's inhaled CF antibiotic franchise (Colfinair, Vantobra) and orphan-drug strategy.
- PARI Pharma GmbH: Manufacturer of the eFlow nebulizer platform and the originator of the inhaled antibiotics (Colfinair, Vantobra) that Neupharma distributes in Italy. Direct technology and product partner for the same CF respiratory franchise.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Neupharma compliance and trust
Trust signalCompliance1 record
Neupharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neupharma leadership team
Management profileNumber of profiles
Profiles2 records
Neupharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neupharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neupharma
What does Neupharma do?
Neupharma is an Italian specialty pharmaceutical company that distributes and markets prescription drugs, medical devices, and foods for special medical purposes focused on cystic fibrosis care. Its portfolio includes inhaled antibiotics (Colfinair, Vantobra) for Pseudomonas aeruginosa infections, PARI respiratory therapy devices and nebulizers, nasal washing devices (Naridek), and CF-targeted nutritional supplements (DKx, DKD, WADI, DALVIK, Yoxa). The company is the exclusive Italian distributor for PARI Pharma GmbH and also distributes the FRIP low-phosphorus cheese line for nephrology patients.
Is Neupharma a public or private company?
Neupharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Neupharma founded?
Neupharma was founded in 2012. It employs 11 to 50 people.
Where is Neupharma based?
Neupharma is headquartered in Imola, Italy, in the Europe region.
How does Neupharma make money?
Four revenue lines are on record. Pharmaceutical Distribution is the primary driver. The others are medical Devices, foods for Medical Purposes and FRIP Low-Phosphorus Foods.
Who are Neupharma's main competitors?
Emerging players on record are Atea Pharmaceuticals and Savara Inc.. Broad incumbents are Vertex Pharmaceuticals, Vectura Group, Chiesi Farmaceutici, Zambon and Recordati S.p.A.. Dompé Farmaceutici is listed as a regional player. Direct peers are Insmed Incorporated and PARI Pharma GmbH.
Does Neupharma have an API?
No public API is recorded for Neupharma.
What industry is Neupharma in?
Neupharma's product category is Specialty Pharmaceuticals (Cystic Fibrosis & Rare Diseases). Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 424210 and its SIC code is 2834.